Marconato L, Ruess-Melzer K, Buchholz J, Kaser-Hotz B
Animal Oncology and Imaging Center, Hünenberg/ZG.
Schweiz Arch Tierheilkd. 2011 Aug;153(8):351-60. doi: 10.1024/0036-7281/a000221.
In human oncology, novel targeted therapy focusing on monoclonal antibodies and tyrosine kinase inhibitors has become an attractive anticancer strategy. The introduction of antiangiogenetic drugs and metronomic chemotherapy has also increased the therapeutic arsenal. Chemotherapy still plays a key role in the treatment of many tumors affecting dogs and cats. However, novel anticancer strategies (including tyrosine kinase inhibitors and monoclonal antibodies, as well as antiangiogenetic treatments) are becoming relevant in veterinary medicine, too. The goal of this review is to describe new therapeutic strategies for cancer treatment in veterinary medicine, including less well-known chemotherapeutic drugs.
在人类肿瘤学中，聚焦于单克隆抗体和酪氨酸激酶抑制剂的新型靶向治疗已成为一种颇具吸引力的抗癌策略。抗血管生成药物和节拍化疗的引入也增加了治疗手段。化疗在治疗许多影响犬猫的肿瘤方面仍发挥着关键作用。然而，新型抗癌策略（包括酪氨酸激酶抑制剂、单克隆抗体以及抗血管生成治疗）在兽医学中也正变得越来越重要。本综述的目的是描述兽医学中癌症治疗的新策略，包括一些不太知名的化疗药物。
